EGFR

Pembrolizumab demonstrate effectiveness beyond five years as a first-line treatment for advanced NSCLC with PD-L1 expression

First-line treatment with pembrolizumab (Keytruda) has demonstrated long-term survival benefits and durable responses in patients with PD-L1-positive, locally advanced or ...